China's I-Mab Inks $548 Million Immunoncology Pact with Genexine

China 's I-Mab Biopharma inked a $548 million agreement with Genexine of South Korea to in-license China rights to Genexine's immunoncology candidate, HyLeukin. I-Mab paid $12 million upfront and is responsible for the remainder in milestones, plus royalties on sales. HyLeukin uses Interleukin-7, a factor in the proliferation and homeostasis of T cells, to create the immunotherapy. Genexine is a prolific dealmaker with China pharmas -- it is a major investor in I-Mab and has forged several deals with Tasly Pharma, also an investor in I-Mab along with C-Bridge Capital. More details.... Stock Symbols: (KOSDAQ, 095700) (SHA: 600535) Share this with colleagues: // //